Aastrom makes Dan Orlando interim CEO
This article was originally published in Scrip
Aastrom Biosciences, a developer of patient-specific, expanded multicellular therapies for the treatment of cardiovascular diseases, has appointed Dan Orlando interim CEO. Mr Orlando, who joined Aastrom as chief commercial officer in August, will assume his new role effective 14 December 2012. Aastrom's current president and CEO Tim Mayleben is retiring but will remain on the company's board of directors.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.